Sugi Predict

Sugi Predict / Targets / BACE2

BACE2

Beta-secretase 2 · Q9Y5Z0 · BACE2 on Sugi Atlas →

81,562 patent compounds predicted against BACE2, 50,407 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL568163 SCHEMBL568163 1.00 20/20
SCHEMBL568164 SCHEMBL568164 1.00 20/20
SCHEMBL568292 SCHEMBL568292 1.00 20/20
SCHEMBL568293 SCHEMBL568293 1.00 20/20
SCHEMBL568304 SCHEMBL568304 1.00 20/20
SCHEMBL568305 SCHEMBL568305 1.00 20/20
SCHEMBL568462 SCHEMBL568462 1.00 20/20
SCHEMBL568463 SCHEMBL568463 1.00 20/20
SCHEMBL568485 SCHEMBL568485 1.00 20/20
SCHEMBL568486 SCHEMBL568486 1.00 20/20
SCHEMBL568498 SCHEMBL568498 1.00 20/20
SCHEMBL568499 SCHEMBL568499 1.00 20/20
SCHEMBL568500 SCHEMBL568500 1.00 20/20
SCHEMBL568540 SCHEMBL568540 1.00 20/20
SCHEMBL568541 SCHEMBL568541 1.00 20/20
SCHEMBL568562 SCHEMBL568562 1.00 20/20
SCHEMBL568563 SCHEMBL568563 1.00 20/20
SCHEMBL568165 SCHEMBL568165 0.88 20/20
SCHEMBL568166 SCHEMBL568166 0.88 20/20
SCHEMBL568405 SCHEMBL568405 0.85 20/20

Clinical trials — most relevant to BACE2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline PHASE4COMPLETED
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) PHASE4COMPLETED
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) PHASE2/PHASE3COMPLETED
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease PHASE3UNKNOWN
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. PHASE2/PHASE3COMPLETED
Longitudinal Study of Brain Amyloid imaGing in MEMENTO PHASE3COMPLETED
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. PHASE2/PHASE3ACTIVE_NOT_RECRUITING
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease PHASE2COMPLETED
Clinical Evaluation of Florbetapir F 18 (18F-AV-45) PHASE2COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2COMPLETED
Study of LM11A-31-BHS in Mild-moderate AD Patients PHASE1/PHASE2COMPLETED
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) PHASE1COMPLETED
Exploratory and Safety Study of [F-18]W372 EARLY_PHASE1COMPLETED
Bace1as Role in Heart Failure (BACE1AS-HF) nanCOMPLETED
Online Neuropsychological Test Validation Project With Imaging Pilot nanCOMPLETED
Dominantly Inherited Alzheimer Network (DIAN) nanRECRUITING
Epilepsy in Alzheimer's Disease: Effect on Disease Progression nanUNKNOWN
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD) nanCOMPLETED
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure nanUNKNOWN
Clearance Mechanisms in Atypical Neurodegenerative Diseases nanUNKNOWN
Inflammatory Biomarkers in Seizure nanUNKNOWN
The Swedish BioFINDER - Primary Care Study nanRECRUITING
Late Onset Alzheimer's Disease nanRECRUITING
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients nanCOMPLETED
The Swedish BioFINDER 2 Study nanRECRUITING
New Biomarker for Alzheimer's Disease Diagnostic nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BACE2 binder may also engage these)

ProteinNameSimilarity
Q6IE75 — 1.000 Q6IE75 →
Q9JL18 — 1.000 Q9JL18 →
W8W138 — 0.985 W8W138 →
Q9M9A8 — 0.976 Q9M9A8 →
Q9WTZ2 — 0.975 Q9WTZ2 →
Q9LX20 — 0.972 Q9LX20 →
Q9S9K4 — 0.972 Q9S9K4 →
C5PEI9 — 0.972 C5PEI9 →
Q9Z2A8 — 0.971 Q9Z2A8 →
Q0WUG6 — 0.971 Q0WUG6 →
Q9WTZ3 — 0.971 Q9WTZ3 →
MBTPS1 Membrane-bound transcription factor site-1 protease 0.970 landscape →
Q26721 — 0.970 Q26721 →
Q0IU52 — 0.970 Q0IU52 →
D4D8U6 — 0.970 D4D8U6 →
Q9XEC4 — 0.969 Q9XEC4 →
Q42456 — 0.968 Q42456 →
D4DGR1 — 0.968 D4DGR1 →
P42210 — 0.968 P42210 →
Q3V1T4 — 0.968 Q3V1T4 →
D4AZK1 — 0.967 D4AZK1 →
Q8VYL3 — 0.967 Q8VYL3 →
A2ZC67 — 0.967 A2ZC67 →
Q4KLM6 — 0.967 Q4KLM6 →
NPR3 Atrial natriuretic peptide receptor 3 0.967 landscape →
Q32P28 — 0.966 Q32P28 →
Q9JLC4 — 0.966 Q9JLC4 →
D4AT39 — 0.966 D4AT39 →
Q9FSV7 — 0.966 Q9FSV7 →
P60016 — 0.966 P60016 →